Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Candriam S.C.A.

Candriam S.C.A. raised its holdings in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 15.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,534,230 shares of the company's stock after purchasing an additional 341,431 shares during the quarter. Candriam S.C.A. owned 2.38% of Annexon worth $13,001,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ANNX. FMR LLC boosted its stake in shares of Annexon by 3.2% in the third quarter. FMR LLC now owns 8,561,949 shares of the company's stock valued at $50,687,000 after buying an additional 262,229 shares in the last quarter. State Street Corp lifted its holdings in Annexon by 116.6% in the third quarter. State Street Corp now owns 3,841,879 shares of the company's stock valued at $22,744,000 after acquiring an additional 2,068,294 shares during the period. Geode Capital Management LLC boosted its position in shares of Annexon by 18.3% during the 3rd quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company's stock worth $12,693,000 after purchasing an additional 331,269 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Annexon by 16.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company's stock worth $10,101,000 after purchasing an additional 235,810 shares during the period. Finally, Sio Capital Management LLC purchased a new position in shares of Annexon in the 3rd quarter valued at about $8,484,000.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ANNX. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Annexon in a report on Tuesday, December 17th. Cantor Fitzgerald reissued an "overweight" rating on shares of Annexon in a research note on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Annexon in a research note on Tuesday, March 4th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $15.80.

Remove Ads

Annexon Stock Up 2.3 %

Shares of ANNX traded up $0.06 during mid-day trading on Tuesday, reaching $2.67. 1,029,836 shares of the company's stock were exchanged, compared to its average volume of 1,801,712. Annexon, Inc. has a 52-week low of $2.30 and a 52-week high of $8.40. The company has a 50-day simple moving average of $3.70 and a two-hundred day simple moving average of $5.30. The company has a market cap of $292.93 million, a price-to-earnings ratio of -2.54 and a beta of 1.14.

Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.05). As a group, equities research analysts predict that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.